Starpharma adds to STI inhibition
Thursday, 04 December, 2008
The main ingredient in Melbourne biotech Starpharma’s developmental microbicide has shown activity in vivo against human papillomavirus 16 and 18, the company said.
These two strains of HPV are responsible for the vast majority of cervical cancers. Starpharma is developing a topically applied microbicide called VivaGel to reduce the risk of infection by several sexually transmitted diseases, including HPV, genital herpes and HIV.
The company said pre-clinical trials had shown the active ingredient, SPL7013, showed activity against HPV 16 and 18, in addition to previously shown activity against HPV 6 and 11, which cause genital warts.
The compound also demonstrated activity against two other minor strains of HPV that are thought to cause a low rate of cervical cancer but are not covered by the available cervical cancer vaccines.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
